A Phase Iv, Multicenter, Open-Label Study Of Emicizumab Prophylaxis In Persons With Hemophilia A With Or Without Fviii Inhibitors Undergoing Minor Surgical Procedures
BLOOD(2020)
Abstract
Introduction: Emicizumab is a subcutaneously administered, bispecific, humanized monoclonal antibody that bridges factor (F)IXa and FX to restore the function of missing activated FVIII in persons with hemophilia A (PwHA). This study (NCT03361137) was designed to evaluate the safety and efficacy of emicizumab prophylaxis in PwHA with or without FVIII inhibitors undergoing minor surgical procedures without additional prophylaxis with bypassing agents (BPAs; for patients with FVIII inhibitors) or FVIII (for patients without FVIII inhibitors).
MoreTranslated text
Key words
emicizumab prophylaxis,hemophilia,fviii inhibitors,open-label
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined